My ePortfolio Register   

Optimal treatment schedule for pomalidomide in multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.11
Views: 4436

Prof Gareth Morgan, Royal Marsden Hospital, London, UK and Dr Xavier Leleu, Hôpital Huriez, CHRU Lille, France

Prof Gareth Morgan sits down with Dr Xavier Leleu to discuss developments on a trial that examines treatment with pomalidomide.  Dr Leleu notes that treatment with pomalidomide would be effective advance myeloma as more and more patients are exposed to other treatments and develop resistance.


The aim of Dr Leleu’s is to find the optimal design for treatment with pomalidomide, finding the safest schedule and the most active.  Basic results have been no difference between the two arms of the study, but both arms had an increase in long term response.  Dr Leleu discusses the benefits of methods of administering pomalidomide and future research taking place.


This programme was made possible with an educational grant provided by CELGENE.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence